Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
opioid dependence
Pharma
Indivior grounds schizophrenia drug, triggering 130 layoffs
Indivior has slashed its projected revenue increase for 2024 from 18% to 8%, citing competitive pressure for top-selling product Sublocade.
Kevin Dunleavy
Jul 10, 2024 11:39am
BMJ report digs into Mallinckrodt's opioid selling tactics
Jun 10, 2024 6:30pm
Amneal resolves opioid lawsuits with $272.5M settlement
May 6, 2024 11:00am
Alkermes grants Teva license to launch generic Vivitrol in 2027
Aug 31, 2023 10:05am
FDA clears Braeburn's Brixadi to treat opioid use disorder
May 24, 2023 10:44am
Love Pharma moves to buy transdermal opioid-use disorder player
Oct 18, 2022 9:20am
